Testing a GD2 CAR T cell therapy in children and young adults with diffuse midline glioma
Original title: CAR T Cells to Target GD2 for DMG
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people, and it is the first stage of testing.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a CAR T cell therapy aimed at GD2 in young people with a brain tumor called diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary.
Who this trial is for. This trial is for children and young adults ages 2 to 16 who have diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, also called DMG. It is testing a CAR T cell therapy that targets GD2. It is a Phase 1 trial at one center, and everyone in it gets the same therapy.
Where it stands. There are no results yet. The trial is looking at whether the therapy can be made for each patient. It is also checking how safe the therapy is and how well people handle it. It is measuring how well the CAR T cells take hold, grow, and last in the body. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: For now, this is a study, not care your own doctor can give you. If your child or family member fits this picture, you can ask your care team about it. Your team can help you think through whether looking into a trial makes sense.
What it doesn't mean: This does not mean the therapy works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help. It is not a promise of a cure, and it does not mean anyone can join.
Source: ClinicalTrials.gov, August 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.